COSCIENS Biopharma Inc
TSX:CSCI
COSCIENS Biopharma Inc
Cash from Operating Activities
COSCIENS Biopharma Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
COSCIENS Biopharma Inc
TSX:CSCI
|
Cash from Operating Activities
-$12.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
9%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$1.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-113%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Operating Activities
$7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$92.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$231.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-48%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$9.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
See Also
What is COSCIENS Biopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-12.2m
USD
Based on the financial report for Mar 31, 2025, COSCIENS Biopharma Inc's Cash from Operating Activities amounts to -12.2m USD.
What is COSCIENS Biopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
9%
Over the last year, the Cash from Operating Activities growth was 30%. The average annual Cash from Operating Activities growth rates for COSCIENS Biopharma Inc have been -11% over the past three years , -4% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet